SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr Reddy's gets prelim FDA nod for asthma drug

10 Jun 2010 Evaluate

Dr Reddy's Laboratories (REDY.BO) has got tentative approval from U.S. regulators to launch the generic version of AstraZeneca's (AZN.L) Accolate, used to treat asthma.

The company is currently working on manufacturing plans for zafirlukast, the generic name of Accolate, and will decide the time of its launch after getting the final approval from the U.S. Food & Drug Administration. The company expects the launch of more than a dozen new drugs in the United States to boost growth in this financial year. crackcrack

Dr. Reddys Lab Share Price

1235.40 14.15 (1.16%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×